Table A7.
Multivariable Cox Proportional Hazards Model of Survival in EPN_PFA
| Variable | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| All cohorts (PFS, n = 645; OS, n = 646) | ||||
| Age | 0.98 (0.96 to 1.00) | .08 | 0.99 (0.96 to 1.01) | .26 |
| Incomplete resection | 1.71 (1.37 to 2.14) | < .001 | 2.05 (1.52 to 2.76) | < .001 |
| Adjuvant radiation | 0.64 (0.50 to 0.82) | < .001 | 0.52 (0.38 to 0.72) | < .001 |
| Adjuvant chemotherapy | 1.04 (0.81 to 1.35) | .74 | 0.89 (0.63 to 1.26) | .51 |
| Male | 1.31 (1.05 to 1.62) | .02 | 1.39 (1.04 to 1.85) | .02 |
| GENE cohort (PFS, n = 258; OS, n = 259) | ||||
| Age | 0.96 (0.93 to 0.99) | .007 | 0.96 (0.91 to 1.00) | .03 |
| Incomplete resection | 1.68 (1.17 to 2.42) | .005 | 2.26 (1.46 to 3.49) | < .001 |
| Adjuvant radiation | 0.31 (0.21 to 0.45) | < .001 | 0.28 (0.18 to 0.45) | < .001 |
| Adjuvant chemotherapy | 1.08 (0.74 to 1.58) | .68 | 0.78 (0.49 to 1.25) | .30 |
| Male | 1.10 (0.79 to 1.55) | .57 | 1.17 (0.77 to 1.78) | .46 |
| CERN cohort (PFS, n = 86; OS, n = 86) | ||||
| Age | 1.00 (0.96 to 1.04) | .92 | 1.01 (0.97 to 1.06) | .53 |
| Incomplete resection | 1.63 (0.85 to 3.12) | .14 | 1.80 (0.83 to 3.88) | .13 |
| Adjuvant radiation | 0.73 (0.43 to 1.25) | .25 | 0.61 (0.31 to 1.18) | .14 |
| Adjuvant chemotherapy | 0.89 (0.46 to 1.72) | .73 | 0.77 (0.35 to 1.67) | .50 |
| Male | 1.40 (0.81 to 2.43) | .23 | 2.51 (1.18 to 5.33) | .02 |
| St Jude’s RT1 cohort (PFS, n = 104; OS, n = 104) | ||||
| Age | 1.00 (0.90 to 1.12) | .94 | 1.04 (0.91 to 1.19) | .61 |
| Incomplete resection | 2.71 (0.40 to 5.26) | .003 | 3.26 (1.49 to 7.12) | .003 |
| Male | 2.42 (1.25 to 4.69) | .009 | 2.86 (1.21 to 6.77) | .02 |
| Burdenko cohort (PFS, n = 197; OS, n = 197) | ||||
| Age | 0.99 (0.96 to 1.03) | .77 | 1.01 (0.96 to 1.06) | .70 |
| Incomplete resection | 1.88 (1.30 to 2.71) | < .001 | 1.84 (1.08 to 3.12) | .02 |
| Adjuvant radiation | 1.12 (0.74 to 1.70) | .60 | 1.02 (0.56 to 1.85) | .94 |
| Adjuvant chemotherapy | 0.98 (0.64 to 1.49) | .92 | 1.42 (0.73 to 2.78) | .30 |
| Male | 1.19 (0.81 to 1.77) | .38 | 0.89 (0.51 to 1.53) | .66 |
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.